Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update

Dominari Holdings Inc. (NASDAQ:DOMH) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totaling 577,094 shares, a growth of 18.8% from the March 15th total of 485,693 shares. Approximately 8.0% of the company’s stock are sold short. Based on an average daily volume of 175,449 shares, the days-to-cover ratio is presently 3.3 days.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Dominari currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Dominari

Large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC purchased a new position in Dominari during the fourth quarter worth about $50,000. PFG Investments LLC purchased a new position in Dominari during the fourth quarter worth about $53,000. Price T Rowe Associates Inc. MD purchased a new position in Dominari during the fourth quarter worth about $96,000. Oxford Asset Management LLP purchased a new position in Dominari during the fourth quarter worth about $120,000. Finally, Jane Street Group LLC purchased a new position in Dominari during the second quarter worth about $158,000. 42.48% of the stock is currently owned by hedge funds and other institutional investors.

Dominari Price Performance

Dominari stock traded up $0.22 during trading hours on Friday, hitting $3.16. The stock had a trading volume of 31,211 shares, compared to its average volume of 136,396. The stock has a market capitalization of $71.49 million, a price-to-earnings ratio of -0.80 and a beta of 0.80. Dominari has a 1-year low of $2.68 and a 1-year high of $8.40. The stock’s fifty day moving average is $3.12 and its two-hundred day moving average is $4.28.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.